National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
J Hematol Oncol. 2020 Apr 16;13(1):38. doi: 10.1186/s13045-020-00871-9.
Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimilarity in analytical, pre-clinical, and clinical investigations to reference rituximab. With demonstrated pharmacokinetic similarity, a phase 3 multi-center, randomized, parallel, double-blind study (HLX01-NHL03) was subsequently conducted to compare efficacy and safety between HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP) and reference rituximab plus CHOP (R-CHOP) in a total of 407 treatment-naïve, CD20-positive DLBCL patients aged 18-80 years. The primary efficacy endpoint was best overall response rate (ORR) within six cycles of treatment in the per-protocol set (PPS). Secondary endpoints included 1-year efficacy outcomes, safety, and immunogenicity profile. The results showed difference in ORRs [H-CHOP 94.1%; R-CHOP 92.8%] between two treatment groups was 1.4% (95% confidence interval [CI], - 3.59 to 6.32, p = 0.608) which falls within the pre-defined equivalence margin of ± 12%. The safety profile was comparable between the treatment groups, with a similar overall incidence of treatment-emergent adverse events (H-CHOP 99.5%, R-CHOP 99.0%, p = 1.000) and serious adverse events (H-CHOP 34.0%, R-CHOP 32.5%, p = 0.752). This study established bioequivalence in efficacy and safety between HLX01 and reference rituximab. The trial was registered at http://www.chinadrugtrials.org.cn on 26 August 2015 [#CTR20150583].
利妥昔单抗联合化疗在弥漫性大 B 细胞淋巴瘤(DLBCL)患者中已显示出超过 15 年的疗效。HLX01 是在逐步达到生物相似性的方法基础上开发的利妥昔单抗生物类似药,通过分析、临床前和临床研究证明与参考利妥昔单抗的生物相似性。在药代动力学相似的基础上,随后进行了一项多中心、随机、平行、双盲的 III 期研究(HLX01-NHL03),比较了 407 例未经治疗的 CD20 阳性 DLBCL 患者(年龄 18-80 岁)接受 HLX01 联合环磷酰胺、多柔比星、长春新碱和泼尼松(H-CHOP)与参考利妥昔单抗联合 CHOP(R-CHOP)的疗效和安全性。主要疗效终点是治疗方案集(PPS)中 6 个周期内的最佳总缓解率(ORR)。次要终点包括 1 年疗效、安全性和免疫原性。结果显示,两组之间的 ORR 差异[H-CHOP 94.1%;R-CHOP 92.8%]为 1.4%(95%置信区间[CI],-3.59 至 6.32,p=0.608),落在预先定义的±12%等效边界内。两组的安全性相似,治疗后出现不良事件的总发生率相似(H-CHOP 99.5%,R-CHOP 99.0%,p=1.000)和严重不良事件(H-CHOP 34.0%,R-CHOP 32.5%,p=0.752)。该研究确立了 HLX01 与参考利妥昔单抗在疗效和安全性方面的生物等效性。该试验于 2015 年 8 月 26 日在中国临床试验注册中心注册(http://www.chinadrugtrials.org.cn),注册号为[CTR20150583]。